The goal of this program is to improve management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. After hearing and assimilating this program, the clinician will be better able to:Cite evidence from the EMILIA trial regarding use of trastuzumab emtansine in breast cancer.List adverse effects of taxane, trastuzumab, pertuzumab therapy as observed in the DESTINY Breast09 trial.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 903 Queens Lane
Pricing
CME included with membership · $1,095/yr
| Platinum Membership | $1,095/yr |
Collected from the provider’s public pages · source
Specialties served/covered
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Breast Imaging
- Cardiac Anesthesia
- Cardiovascular Disease
- Clinical Cardiac Electrophysiology
- Critical Care Medicine
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Facial Plastic & Reconstructive Surgery
- Gastroenterology
- General Internal Medicine
- General Operative Anesthesia
- General Otolaryngology
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Head & Neck Surgery
- Hematology
- Hospice & Palliative Medicine
- Hospital Medicine
- Interventional Radiology
- Laryngology
- Medical Oncology
- Neonatal-Perinatal Medicine
- Nephrology
- Neuro Anesthesia
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neuroradiology
- Nuclear Medicine
- Obstetric Anesthesia
- Otology & Neurotology
- Pain Medicine
- Pediatric Anesthesia
- Pediatric Cardiology
- Pediatric Critical Care Medicine
- Pediatric Emergency Medicine
- Pediatric Gastroenterology
- Pediatric Hematology-Oncology
- Pediatric Infectious Diseases
- Pediatric Neurology
- Pediatric Otolaryngology
- Pediatric Radiology
- Pediatric Surgery
- Primary Care Sports Medicine
- Pulmonary Disease
- Regional Anesthesia & Acute Pain
- Rheumatology
- Rhinology
- Sleep Medicine
- Surgical Critical Care
- Surgical Oncology
- Thoracic Anesthesia
- Trauma Surgery
- Vascular Surgery
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Radiology
- Sports & Exercise Medicine
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Membership pricing — $1,095 / year
This provider prices CME through membership. Individual courses may also be sold separately.
See plans on audio-digest.orgListed by the provider
- Enduring / On-demand
- Credit · Up to 0.75 credits
- MOC · Up to 0.75 points
- Membership pricing
-
ReleasedSep 1, 2026
-
Last day to claim creditDec 8, 2028 2 years left
-
Clinical Care Options, LLC (dba Decera Clinical Education) Strategies for Adjuvant Treatment in HER2+ Early-Stage Breast Cancer
-
Efficient CME, CME Outfitters, LLC Reshaping the Paradigm: Expert Strategies and Ongoing Questions on the Implementation of Novel Frontline Strategies in HER2-Positive Metastatic Breast Cancer
-
Medscape, LLC High-Risk HR-Positive, HER2-Negative Early Breast Cancer: Latest Updates from the European Oncology Congress
